JanOne Wins “Best Abstract” Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

Posted on by

Abstract explained Jan101’s statistically significant reduction in pain and improvement in nerve conduction velocity in prior Phase II study. LAS VEGAS, Aug. 25, 2023 /PRNewswire/ — JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.